Skip to main content

Advertisement

SpringerLink
Log in

Towards a diagnostic and therapeutic consensus in male osteoporosis

  • Position Paper
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

The consensus views on osteoporosis in men are reported.

Introduction

A workshop was convened within a meeting on osteoporosis in men to identify areas of consensus amongst the panel (the authors) and the participants of the meeting.

Methods

A public debate with an expert panel on preselected topics was conducted.

Results and Conclusions

Consensus views were reached on diagnostic criteria and several aspects on the pathophysiology and treatment of osteoporosis in men.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series 843. WHO, Geneva

    Google Scholar 

  2. Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9:17–1141

    Google Scholar 

  3. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ, Khaltaev N (2008) A reference standard for the description of osteoporosis. Bone 42:467–475

    Article  PubMed  CAS  Google Scholar 

  4. Kanis JA, Glüer CC, for the Committee of Scientific Advisors, International Osteoporosis Foundation (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11:192–202

    Article  PubMed  CAS  Google Scholar 

  5. Melton LJ III, Atkinson EJ, O’Connor MK, O’Fallon WM, Riggs BL (1998) Bone density and fracture risk in men. J Bone Miner Res 13:1915–1923

    Article  PubMed  Google Scholar 

  6. Melton LJ III, Orwoll ES, Wasnich RD (2001) Does bone density predict fractures comparably in men and women? Osteoporos Int 12:707–709

    Article  PubMed  Google Scholar 

  7. Cummings SR, Cawthon PM, Ensrud KE et al (2006) BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res 21:1550–6

    Article  PubMed  Google Scholar 

  8. Johnell O, Kanis JA, Oden A et al (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185–1194

    Article  PubMed  Google Scholar 

  9. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D (2001) Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int 69:218–221

    Article  PubMed  CAS  Google Scholar 

  10. Orwoll E (2000) Assessing bone density in men. J Bone Miner Res 15:1867–1870

    Article  PubMed  CAS  Google Scholar 

  11. Selby PL, Davies M, Adams JE (2000) Do men and women fracture bones at similar bone densities. Osteoporos Int 11:153–157

    Article  PubMed  CAS  Google Scholar 

  12. Lunt M, Felsenberg D, Reeve J et al (1997) Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. J Bone Miner Res 12:1883–94

    Article  PubMed  CAS  Google Scholar 

  13. Nguyen T, Sambrook P, Kelly P et al (1993) Prediction of osteoporotic fractures by postural instability and bone density. Br Med J 307:1111–1115

    Article  CAS  Google Scholar 

  14. DeLaet CED, van Hout BA, Burger H, Hoffman A, Pols HAP (1997) Bone density and risk of hip fracture in men and women: cross sectional analysis. Brit Med J 315:221–225

    CAS  Google Scholar 

  15. DeLaet CEDH, Van Hout BA, Burger H, Hofman A, Weel AEAM, Pols HAP (1998) Hip fracture prediction in elderly men and women: validation in the Rotterdam Study. J Bone Miner Res 13:1587–1593

    Article  CAS  Google Scholar 

  16. Wasnich RD, Davis JW, Ross PD (1994) Spine fracture risk is predicted by non spine fractures. Osteoporos Int 4:1–5

    Article  PubMed  CAS  Google Scholar 

  17. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to World Health Organization criteria for osteoporosis and osteopenia. Bone 27:585–590

    Article  PubMed  CAS  Google Scholar 

  18. Currey JD (2002) Bones: structure and mechanics. Princeton University Press, Princeton, pp 1–380

    Google Scholar 

  19. Parfitt AM (2008) Skeletal heterogeneity and the purposes of bone remodeling: Implications for the understanding of osteoporosis. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Academic, San Diego, pp 71–89

    Chapter  Google Scholar 

  20. Seeman E, Delmas PD (2006) Bone quality—the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–61

    Article  PubMed  CAS  Google Scholar 

  21. Lips P, Courpron P, Meunier PJ (1978) Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26:13–7

    Article  PubMed  CAS  Google Scholar 

  22. Garnero P, Sorney-Rendu E, Duboeuf F, Delmas PD (1999) Markers of bone turnover predict postmenopausal bone loss over 4 years: the OFELY study. J Bone Miner Res 14:1614–21

    Article  PubMed  CAS  Google Scholar 

  23. Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS (2004) Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Oncol 22:2546–63

    Article  CAS  Google Scholar 

  24. Balena R, Shih M-S, Parfitt AM (1992) Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res 7:1475–1482

    Article  PubMed  CAS  Google Scholar 

  25. Aaron JE, Makins NB, Sagreiya K (1987) The microanatomy of trabecular bone loss in normal aging men and women. Clin Orthop Relat Res 215:260–71

    PubMed  Google Scholar 

  26. Zebaze R, Ghasem-Zadeh A, Bohte A et al (2010) Intracortical remodeling and porosity: rational targets for fracture prevention. Lancet 375:1729–36

    Article  PubMed  Google Scholar 

  27. Burghardt AJ, Buie HR, Laib A, Majumdar S, Boyd SK (2010) Rreproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT. Bone 47:519–28

    Article  PubMed  Google Scholar 

  28. Burghardt AJ, Kazakia GJ, RamachandranS LTM, Majumdar S (2010) Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res 25:983–93

    Article  PubMed  Google Scholar 

  29. Bass S, Delmas PD, Pearce G, Hendrich E, Tabensky A, Seeman E (1999) The differing tempo of growth in bone size, mass and density in girls is region-specific. J Clin Invest 104:795–804

    Article  PubMed  CAS  Google Scholar 

  30. Duan Y, Wang XF, Evans A, Seeman E (2005) Structural and biomechanical basis of racial and sex differences in vertebral fragility in Chinese and Caucasians. Bone 36:987–98

    Article  PubMed  Google Scholar 

  31. Riggs BL, Melton LJ III, Robb RA et al (2004) A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 19:1945–54

    Article  PubMed  Google Scholar 

  32. Seeman E (2003) Periosteal bone formation—a neglected determinant of bone strength. N Engl J Med 349:320–3

    Article  PubMed  Google Scholar 

  33. Ural A, Vashishth D (2006) Interactions between microstructural and geometrical adaptation in human cortical bone. J Orthop Res 24:1489–98

    Article  PubMed  Google Scholar 

  34. Nalla RK, Kruzic JJ, Kinney JH et al (2010) Role of microstructure in the aging-related deterioration of the toughness of human cortical bone. Mater Sci Eng, C 26:1251–1260

    Article  Google Scholar 

  35. Yeni YN, Brown CU, Wang Z, Norman TL (1997) The influence of bone morphology on fracture toughness of the human femur and tibia. Bone 21:453–9

    Article  PubMed  CAS  Google Scholar 

  36. Currey JD (1988) The effect of porosity and mineral content on the Young’s modulus of elasticity of compact bone. J Biomech 21:131–139

    Article  PubMed  CAS  Google Scholar 

  37. Ciarelli TE, Fyhrie DP, Parfitt AM (2003) Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 32:311–5

    Article  PubMed  CAS  Google Scholar 

  38. Qiu S, Rao DS, Fyhrie DP, Palnitkar S, Parfitt AM (2005) The morphological association between microcracks and osteocyte lacunae in human cortical bone. Bone 37:10–15

    Article  PubMed  Google Scholar 

  39. Zebaze R, Seeman E, Ghasem-Zadeh A et al (2010) Analysis system and method. Australian Provisional Patent No. 2009904407

  40. Saito M, Marumo K (2010) Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int 21:195–214

    Article  PubMed  CAS  Google Scholar 

  41. Tang SY, Zeenath U, Vashishth D (2007) Effects of non-enzymatic glycation on cancellous bone fragility. Bone 40:1144–51

    Article  PubMed  CAS  Google Scholar 

  42. Duan Y, Seeman E, Turner CH (2001) The biomechanical basis of vertebral body fragility in men and women. J Bone Miner Res 16:2276–2283

    Article  PubMed  CAS  Google Scholar 

  43. Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610

    Article  PubMed  CAS  Google Scholar 

  44. Ho YV, Frauman AG, Thomson W, Seeman E (2000) Effects of alendronate on bone density in men with primary and secondary osteoporosis. Osteoporos Int 11:98–101

    Article  PubMed  CAS  Google Scholar 

  45. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076

    Article  PubMed  CAS  Google Scholar 

  46. Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med 344:1434–1441

    Article  CAS  Google Scholar 

  47. Orwoll ES, Scheele WH, Paul S et al (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9–17

    Article  PubMed  CAS  Google Scholar 

  48. Gonnell S, Cepoliano C, Montagnani A et al (2003) Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 73:133–159

    Article  Google Scholar 

  49. Drake WM, Kendler DL, Rosen CJ, Orwoll ES (2003) An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 88:5759–5765

    Article  PubMed  CAS  Google Scholar 

  50. Miller PD, Schnitzer T, Emkey R et al (2004) Weekly oral alendronic acid in male osteoporosis. Clin Drug Invest 24l:333–341

    Article  Google Scholar 

  51. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 24:719–725

    Article  PubMed  CAS  Google Scholar 

  52. Ringe JD, Farahmand P, Faber K, Dorst A (2009) Sustained efficacy of risedronate in men with primary and secondary osteporoosis: results of a 2-year study. Rheumatol Int 29:311–315

    Article  PubMed  CAS  Google Scholar 

  53. Orwoll ES, Miller PD, Adachi JD et al (2010) Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 25:2239–2250

    Article  PubMed  CAS  Google Scholar 

  54. Orwoll ES, Binkley NC, Lweiecki EM, Gruntmanis U, Fries MA, Dasic G (2010) Efficacy and safety of monthly ibandronate in men with low bone density. Bone 46:970–976

    Article  PubMed  CAS  Google Scholar 

  55. Boonen S, Kaufman JM, Reginster J-Y et al (2011) Antifracture efficacy and safety of once-yearly zoledronic acid 5 mg in men with osteoporosis: a prospective, randomised, controlled trial. Osteoporos Int 22 (Suppl 1):S180

    Google Scholar 

  56. Smith MR, Egerdie B, Hernández Toriz N, Denosumab HALT Prostate Cancer Study Group et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745–55

    Article  PubMed  CAS  Google Scholar 

  57. World Health Organization (1998) Guidelines for preclinical evaluation and clinical trials in osteoporosis. WHO, Geneve

    Google Scholar 

  58. Lang T, Cauley JA, Tylavsky F, BauerD CS, Harris TB (2010) Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: The health, aging, and body composition study. J Bone Miner Res 25:513–519

    Article  PubMed  Google Scholar 

  59. Lewis CE, Ewing SK, Taylor BC et al (2007) Predictors of non-spine fracture in elderly men: the MrOS study. J Bone Miner Res 22:211–219

    Article  PubMed  Google Scholar 

  60. Cummings SR, Nevitt MC, Browner WS et al (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767–773

    Article  PubMed  CAS  Google Scholar 

  61. Cawthon PM, Fullman RL, Marshall L et al (2008) Physical performance and risk of hip fractures in older men. J Bone Miner Res 23:1037–44

    Article  PubMed  Google Scholar 

  62. Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R (2010) Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 153:815–825

    PubMed  Google Scholar 

  63. Bischoff-Ferrari HA, Orav EJ, Dawson-Hughes B (2006) Effect of cholecalciferol plus calcium on falling in ambulatory older men and women: a 3-year randomized controlled trial. Arch Intern Med 166:424–430

    Article  PubMed  CAS  Google Scholar 

  64. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340

    Article  PubMed  CAS  Google Scholar 

  65. De Laet C, Kanis JA, Oden A et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330–8

    Article  PubMed  Google Scholar 

  66. Flegal KM, Carroll MD, Ogden CL et al (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–41

    Article  PubMed  CAS  Google Scholar 

  67. Sundquist J, Johnansson S-E, Sundquist K (2010) Levelling off of prevalence of obesity in the adult population of Sweden between 2000/01 and 2004/05. BMC Public Health 2010:10

    Google Scholar 

  68. Nielson CM, Marshall LM, Adams AL et al (2010) BMI and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 26(3):496–502

    Article  Google Scholar 

  69. Freitas SS, Barrett-Connor E, Ensrud KE et al (2008) Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 19:615–623

    Article  PubMed  CAS  Google Scholar 

  70. Khosla S, Amin S, Orwoll E (2008) Osteoporosis in men. Endocr Rev 29:441–464

    Article  PubMed  CAS  Google Scholar 

  71. Peacock M, Koller DL, Lai D, Hui S, Foroud T, Econs MJ (2009) Bone mineral density variation in men is influenced by sex-specific and non sex-specific quantitative trait loci. Bone 45:443–448

    Article  PubMed  CAS  Google Scholar 

  72. Khosla S, Melton LJ III, Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL (1998) Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266–2274

    Article  PubMed  CAS  Google Scholar 

  73. Rapado A, Hawkins F, Sobrinho L et al (1999) Bone mineral density and androgen levels in elderly males. Calcif Tissue Int 65:417–21

    Article  PubMed  CAS  Google Scholar 

  74. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S (2000) Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553–1560

    Article  PubMed  CAS  Google Scholar 

  75. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS (2003) Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88:204–210

    Article  PubMed  CAS  Google Scholar 

  76. Khosla S, Melton LJ, Atkinson EJ, O'Fallon WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555–3561

    Article  PubMed  CAS  Google Scholar 

  77. Van Pottelbergh I, Goemaere S, Kaufman JM (2003) Bioavailable estradiol and an aromatase gene polymorphism are determinants of bone mineral density changes in men over 70 years of age. J Clin Endocrinol Metab 88:3075–3081

    Article  PubMed  Google Scholar 

  78. Lapauw B, Taes Y, Goemaere S, Toye K, Zmierczak H-G, Kaufman J-M (2009) Anthropometric and skeletal phenotype in men with idiopathic osteoporosis and their sons is consistent with deficient estrogen action during maturation. J Clin Endocrinol Metab 94:4300–4308

    Article  PubMed  CAS  Google Scholar 

  79. Khosla S, Melton LJ, Riggs BL (2002) Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443–1450

    Article  PubMed  CAS  Google Scholar 

  80. Mellstrom D, Vandenput L, Mallmim H et al (2008) Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res 23:1552–1560

    Article  PubMed  Google Scholar 

  81. Riggs BL, Melton LJ (1986) Medical progress series: involutional osteoporosis. N Engl J Med 314:1676–1686

    Article  PubMed  CAS  Google Scholar 

  82. Smith MR (2007) Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diab Obes 14:247–254

    Article  Google Scholar 

  83. Lowe H, Shane E (2008) Osteoporosis associated with illnesses and medications. In: Marcus R, Feldman D, Nelson DA, Rosen CJ (eds) Osteoporosis. Elsevier, San Diego, pp 1283–1314

    Chapter  Google Scholar 

  84. Stepan JJ, Lachman M, Zverina J, Pacovsky V, Baylink DJ (1989) Castrated men exhibit bone loss—effect of calcitonin treatment on biochemical indexes of bone remodeling. J Clin Endocrinol Metab 69:523–527

    Article  PubMed  CAS  Google Scholar 

  85. Stoch SA, Parker RA, Chen LP, Bubley G, KO YJ, Vincelette A, Greenspan SL (2001) Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 86:2787–2791

    Article  PubMed  CAS  Google Scholar 

  86. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM (2002) Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87:3656–3661

    Article  PubMed  CAS  Google Scholar 

  87. Shahinian VB, Kuo Y, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164

    Article  PubMed  CAS  Google Scholar 

  88. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C (2004) Androgens and bone. Endocr Rev 25:389–425

    Article  PubMed  CAS  Google Scholar 

  89. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010

    Article  PubMed  CAS  Google Scholar 

  90. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390

    Article  PubMed  CAS  Google Scholar 

  91. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ (2003) Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 88:3167–3176

    Article  PubMed  CAS  Google Scholar 

  92. Smith MR, Fallon MA, Lee H, Finkelstein JS (2004) Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 89:3841–3846

    Article  PubMed  CAS  Google Scholar 

  93. Michaelson MD, Kaufman DS, Lee H et al (2007) Randomized controlled trial of annual zoledronic acidto prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostatz cancer. J Clin Oncol 25:1038–1042

    Article  PubMed  CAS  Google Scholar 

  94. Greenspan SL, Nelson JB, Trump DL, Resnick NM (2007) Effect of once weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. Ann Intern Med 146:416–424

    PubMed  Google Scholar 

  95. Kaufman JM, Vermeulen A (2005) The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 26:833–876

    Article  PubMed  CAS  Google Scholar 

  96. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta analysis. Clin Endocrinol (oxf) 63:280–293

    Article  CAS  Google Scholar 

  97. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh I, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972

    Article  PubMed  CAS  Google Scholar 

  98. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510

    Article  PubMed  CAS  Google Scholar 

  99. Fernandez-Balsells MM, Murad MH, Lane M et al (2010) Adverse efects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95:2560–2575

    Article  PubMed  CAS  Google Scholar 

  100. Basaria S, Coviello AD, Travison TG et al (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122

    Article  PubMed  CAS  Google Scholar 

  101. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 159:507–14

    Article  PubMed  CAS  Google Scholar 

Download references

Competing interests

JAK has nothing to declare for FRAX and the context of this paper but has numerous ad hoc consultancies for governmental, non-governmental agencies and the pharmaceutical industry. GB and ES have no competing interests with regard to this manuscript. SK is a member of the advisory board for Amgen. JPB is a consultant for Amgen.

Author information

Authors and Affiliations

  1. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK

    J. A. Kanis

  2. Division of Rheumatology, ASL3 Genovese, Genoa, Italy

    G. Bianchi

  3. Columbia University College of Physicians and Surgeons, New York, 10032, USA

    J. P. Bilezikian

  4. Department of Endocrinology, Ghent University Hospital, Ghent, Belgium

    J.-M. Kaufman

  5. College of Medicine, Mayo Clinic, Rochester, MN, USA

    S. Khosla

  6. Bone and Mineral Unit, Oregon Health and Science University, Portland, OR, USA

    E. Orwoll

  7. Department of Endocrinology and Medicine, Austin Health, University of Melbourne, Melbourne, Australia

    E. Seeman

Authors
  1. J. A. Kanis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Bianchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. P. Bilezikian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J.-M. Kaufman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Khosla
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Orwoll
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Seeman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. A. Kanis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kanis, J.A., Bianchi, G., Bilezikian, J.P. et al. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int 22, 2789–2798 (2011). https://doi.org/10.1007/s00198-011-1632-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-011-1632-z

Keywords

Search

Navigation